Fudan University: Breast Neoplasms trials

The registry lists 260 Breast Neoplasms studies with Fudan University as lead sponsor. 117 are open to participants now and 0 have results posted.

Phase 1 12Phase 2 118Phase 3 50Phase 4 6No phase 87(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant TreatmentNot yet recruitingNCT07884201Phase 2
• SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingNCT07856303Phase 2
• Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based ReconstructionRecruitingNCT07835139Not applicable
• 1-Week Versus 3-Week PBIRecruitingNCT07832279Not applicable
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic TherapyRecruitingNCT07829848Not applicable
• Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07826052Phase 2
• Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
• Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer SurgeryEnrolling by invitationNCT07798466
• Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast CancerRecruitingNCT07776301Not applicable
• An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBCNot yet recruitingNCT07760844Phase 3
• Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07716046Phase 2
• An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBCNot yet recruitingNCT07669610Phase 3
• A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.RecruitingNCT07666555Phase 2
• A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast CancerRecruitingNCT07653893
• A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced ThrombocytopeniaeNot yet recruitingNCT07647029Phase 2
• Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer StudyRecruitingNCT07647016Phase 2
• The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.RecruitingNCT07638774Not applicable
• Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerRecruitingNCT07615751Phase 3
• Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.Not yet recruitingNCT07610733Phase 2
• Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic EfficacyRecruitingNCT07574749
• Opportunistic Breast Cancer Screening Using Non-Contrast Chest CTRecruitingNCT07557654
• Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT07551050
• Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyRecruitingNCT07528716Phase 3
• Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast CancerRecruitingNCT07471776Phase 2
• Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastasesRecruitingNCT07469267Not applicable
• CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）RecruitingNCT07432178Phase 3
• ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast CancerNot yet recruitingNCT07423611Phase 2
• A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRINot yet recruitingNCT07419867Phase 2
• Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingNCT07410559Phase 2
• Adjuvant Intensification for LARNot yet recruitingNCT07407517Phase 3
• ctDNA-guided Treatment Decision-makingRecruitingNCT07394218Phase 2
• Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingNCT07382687Phase 3
• Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingNCT07368543Phase 2
• RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingNCT07366840Phase 2/3
• Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin ReactionsRecruitingNCT07362914Phase 3
• Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)Not yet recruitingNCT07353437Phase 2
• A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Not yet recruitingNCT07290166Phase 2
• Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBCRecruitingNCT07290153
• CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast CancerNot yet recruitingNCT07213206Phase 3
• SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd TreatmentRecruitingNCT07182721Phase 2
• Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingNCT07134153Phase 1/2
• An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyRecruitingNCT07117630Phase 2
• Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC PatientsNot yet recruitingNCT07021261Phase 3
• CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)RecruitingNCT07019363Phase 3
• Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07005557Phase 3
• Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 InhibitorNot yet recruitingNCT06996093Phase 3
• Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast CancerNot yet recruitingNCT06977542Phase 2
• Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization StageNot yet recruitingNCT06965556Not applicable
• Breast Cancer PET/CT Imaging With 68Ga-pAKTiEnrolling by invitationNCT06943313
• Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast CancerRecruitingNCT06911528Not applicable
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicable
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast CancerNot yet recruitingNCT06798506
• Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast CancerNot yet recruitingNCT06797622Phase 2
• Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer PatientsNot yet recruitingNCT06795503Phase 3
• BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingNCT06793332Phase 2
• Capecitabine in Low Risk Triple Negative Breast CancerRecruitingNCT06787339Phase 2
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingNCT06786026Phase 2
• JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingNCT06731153Phase 2
• Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
• The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast CancerRecruitingNCT06718010
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
• AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled TrialRecruitingNCT06642948Not applicable
• Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast CancerRecruitingNCT06637150Phase 3
• All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II TrialRecruitingNCT06636981Phase 2
• The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast CancerNot yet recruitingNCT06635096Not applicable
• A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in ChinaRecruitingNCT06591039
• Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast CancerNot yet recruitingNCT06578299Phase 4
• ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXdNot yet recruitingNCT06578286Phase 2
• Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2
• T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2
• Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabRecruitingNCT06516289Phase 2
• Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast CancerRecruitingNCT06503380
• Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast CancerNot yet recruitingNCT06470672Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNot yet recruitingNCT06404736Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNot yet recruitingNCT06404463Phase 2
• clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone MetastasesRecruitingNCT06392217
• LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingNCT06387628Phase 2
• Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingNCT06356519
• Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
• Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibRecruitingNCT06341621Phase 3
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1
• A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain MetastasesNot yet recruitingNCT06088056Phase 2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeRecruitingNCT05954442Phase 3
• T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2
• Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2
• Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PETRecruitingNCT05914402Not applicable
• Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)RecruitingNCT05909332Phase 3
• The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates Classification of Breast LessionsNot yet recruitingNCT05892380
• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3
• A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast CancerNot yet recruitingNCT05889871Phase 3
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerRecruitingNCT05883852Phase 3
• Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier GranulesNot yet recruitingNCT05871437Phase 4
• Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2
• Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisNot yet recruitingNCT05860907Phase 4
• Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerNot yet recruitingNCT05841381Phase 3
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerRecruitingNCT05759546Phase 2
• SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2